NYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis $86.47 +1.20 (+1.40%) Closing price 03:59 PM EasternExtended Trading$86.55 +0.08 (+0.09%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Edwards Lifesciences Stock (NYSE:EW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Edwards Lifesciences alerts:Sign Up Key Stats Today's Range$84.83▼$86.6250-Day Range$84.18▼$93.5952-Week Range$72.40▼$96.29Volume4.04 million shsAverage Volume4.51 million shsMarket Capitalization$49.79 billionP/E Ratio49.69Dividend YieldN/APrice Target$100.27Consensus RatingModerate Buy Company Overview Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories. Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement. Its products are used by hospitals and heart specialists to treat conditions such as aortic stenosis and other heart valve disorders, providing alternatives to traditional open-heart surgery for certain patients. Edwards Lifesciences serves healthcare providers and patients in the United States and international markets across Europe, Asia-Pacific, and other regions. The company is headquartered in Irvine, California, and is led by President and Chief Executive Officer Bernard Zovighian.AI Generated. May Contain Errors. Read More Edwards Lifesciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreEW MarketRank™: 3.871899199365 of 5 starsEdwards Lifesciences scored higher than 77% of companies evaluated by MarketBeat, and ranked 80th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingEdwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 16 buy ratings, 5 hold ratings, and no sell ratings.Upside PotentialEdwards Lifesciences has a consensus price target of $100.27, representing about 16.0% upside from its current price of $86.47.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edwards Lifesciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth13.00% Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 13.00% in the coming year, from $3.00 to $3.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 49.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.74.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 49.69, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.28.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 2.26. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 4.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edwards Lifesciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.66% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 2.46, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently increased by 4.96%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.58 News SentimentEdwards Lifesciences has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Edwards Lifesciences this week, compared to 7 articles on an average week.Search Interest12 people have searched for EW on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows6 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $451,596.00 in company stock.Percentage Held by Insiders0.31% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Edwards Lifesciences' insider trading history. Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EW Stock News HeadlinesEdwards Lifesciences Earnings Preview: What to ExpectOctober 12 at 5:10 AM | barchart.comEdwards Lifesciences (NYSE:EW) VP Sells $53,017.35 in StockOctober 9, 2026 | insidertrades.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 14 at 1:00 AM | Weiss Ratings (Ad)Barclays initiates coverage of Edwards Lifesciences with overweight ratingOctober 8, 2026 | msn.comWhy Edwards Lifesciences (EW) Stock Is Falling TodayOctober 8, 2026 | quiverquant.comQEdwards Lifesciences (NYSE:EW) Stock Moved Up to Strong-Buy by BarclaysOctober 8, 2026 | americanbankingnews.comBarclays initiates coverage of Edwards Lifesciences at overweightOctober 7, 2026 | msn.comEdwards Lifesciences to Host Earnings Conference Call on November 4, 2026October 7, 2026 | finance.yahoo.comSee More Headlines EW Stock Analysis - Frequently Asked Questions How have EW shares performed this year? Edwards Lifesciences' stock was trading at $85.26 on January 1st, 2026. Since then, EW stock has increased by 1.4% and is now trading at $86.4660. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Corporation (NYSE:EW) announced its quarterly earnings data on Thursday, July, 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. The company's revenue was up 13.6% compared to the same quarter last year. Read the conference call transcript. When did Edwards Lifesciences' stock split? Shares of Edwards Lifesciences split before market open on Friday, May 29th 2020.The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were distributed to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Does Edwards Lifesciences have any subsidiaries? Edwards Lifesciences subsidiaries include CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and others. Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' top institutional shareholders include Seilern Investment Management Ltd (0.10%), Jacobs & Co. CA (0.02%), Weaver Consulting Group (0.01%) and Sivik Global Healthcare LLC (0.01%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Donald E Bobo Jr, Kieran Gallahue, Steven R Loranger, Bernard J Zovighian, Daniel J Lippis, Scott B Ullem, Catherine M Szyman, Daveen Chopra, Heisz Leslie Stone, Annette Bruls, Andrew M Dahl, Robert WA Sellers, Wayne Markowitz and Michael A Mussallem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include NVIDIA (NVDA), Salesforce (CRM), Adobe (ADBE), Visa (V), Mastercard (MA), Broadcom (AVGO) and Intuitive Surgical (ISRG). Company Calendar Last Earnings7/23/2026Today10/14/2026Investor update11/02/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 EW's financial health is in the Green zone, according to TradeSmith. EW has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:EW CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees16,000Year Founded1958Price Target and Rating Average Price Target for Edwards Lifesciences$100.27 High Price Target$110.00 Low Price Target$85.00 Potential Upside/Downside+16.0%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)$1.74 Trailing P/E Ratio49.69 Forward P/E Ratio28.82 P/E Growth2.26Net Income$1.07 billion Net Margins15.43% Pretax Margin21.77% Return on Equity15.68% Return on Assets12.05% Debt Debt-to-Equity Ratio0.06 Current Ratio4.52 Quick Ratio3.77 Sales & Book Value Annual Sales$6.07 billion Price / Sales8.21 Cash Flow$2.85 per share Price / Cash Flow30.30 Book Value$17.81 per share Price / Book4.85Miscellaneous Outstanding Shares575,800,000Free Float574,015,000Market Cap$49.79 billion OptionableOptionable Beta0.87 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSE:EW) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Edwards Lifesciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EW Stock Alerts